Comparative Pharmacology
Head-to-head clinical analysis: RISPERDAL versus SEZABY.
Peer-Reviewed Evidence
Head-to-head clinical analysis: RISPERDAL versus SEZABY.
RISPERDAL vs SEZABY
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Risperidone is a benzisoxazole atypical antipsychotic that antagonizes dopamine D2 and serotonin 5-HT2A receptors. It also blocks alpha1-adrenergic, alpha2-adrenergic, and histamine H1 receptors.
Positive allosteric modulator of GABA-A receptors, enhancing inhibitory neurotransmission.
2-8 mg orally once daily or divided twice daily; maximum 16 mg/day
58 mg subcutaneously once monthly (every 30 days).
None Documented
None Documented
20 hours (parent drug), 23 hours (active metabolite 9-hydroxyrisperidone). Steady state reached in 5-6 days. Extended in elderly and hepatic/renal impairment.
The terminal elimination half-life of Sezaby is approximately 24 hours in healthy adults. This supports once-daily dosing. In patients with hepatic impairment, half-life may be prolonged.
Renal: 70% (30% as unchanged drug, 40% as metabolites), Fecal/Biliary: 14%
Sezaby undergoes extensive hepatic metabolism, with approximately 75% of the dose excreted in feces as metabolites and 20% in urine as unchanged drug and metabolites. Renal clearance accounts for less than 5% of total clearance.
Category C
Category C
Atypical Antipsychotic
Atypical Antipsychotic